DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

Fifty 410 vs NovoCare Pharmacy (Wegovy): November 2026 prices compared

As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; NovoCare Pharmacy (Wegovy) is a brand route with no compounded tirzepatide price, so no like-for-like comparison is possible.

Released · Last reviewed · how we verify

On compounded semaglutide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; NovoCare Pharmacy (Wegovy) is a brand route with no compounded semaglutide price, so no like-for-like comparison is possible.

Fifty 410 and NovoCare Pharmacy (Wegovy), measure by measure

Fifty 410 and NovoCare Pharmacy (Wegovy) side by side, from each program’s own page read November 20, 2026 (all-in: medication plus any required recurring fee, before tax)
MeasureFifty 410NovoCare Pharmacy (Wegovy)
Tirzepatide, month to month$199 (per 28-day cycle)—
Tirzepatide, lowest printed$149.50 (8-week program at $299, not in all states)—
Semaglutide, month to month$199 (per 28-day cycle)—
Semaglutide, lowest printed$199 (4-week program)—
Dose pricingpriced by dose or not statedpriced by dose or not stated
Membership or program feenonenone
Computed score23.5 of 40 (position 8 of 27)not scored (brand route)
FDA warning letters721481 (2026-02-20)none listed
November 20 readfirst-party read, changedfirst-party read

Strengths and limitations: which fits whom

Fifty 410 bills every 28 days, which adds a 13th charge to the year. NovoCare Pharmacy (Wegovy) suits someone who wants brand medication, FDA-approved, and accepts a higher monthly cost or has coverage. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.

What changed since August

The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.

What changed since the August 2026 capture (maintenance-dose all-in figure then; month-to-month all-in figure read November 20, 2026)
ProgramMedicationAugust 5–10, 2026November 20, 2026
Fifty 410tirzepatide—$199
Fifty 410semaglutide—$199

Regulatory record

FDA’s warning-letter index lists warning letter 721481 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to Fifty 410; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Check Fifty 410’s current prices ↗
Check NovoCare Pharmacy (Wegovy)’s current prices ↗

Frequently asked

Which is cheaper, Fifty 410 or NovoCare Pharmacy (Wegovy)?

On compounded tirzepatide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; NovoCare Pharmacy (Wegovy) is a brand route with no compounded tirzepatide price, so no like-for-like comparison is possible. On compounded semaglutide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; NovoCare Pharmacy (Wegovy) is a brand route with no compounded semaglutide price, so no like-for-like comparison is possible.

Do Fifty 410 and NovoCare Pharmacy (Wegovy) charge a membership fee?

Fifty 410: no membership fee; NovoCare Pharmacy (Wegovy): no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.

Are Fifty 410 and NovoCare Pharmacy (Wegovy) medications FDA-approved?

Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.

Fifty 410 recordNovoCare Pharmacy (Wegovy) recordAll head-to-headsRankingsPrice database

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.